Pasadena, Calif., July 10, 2018 (GLOBE NEWSWIRE) — Meditope Biosciences, Inc., a biotechnology company developing novel oncology therapeutics using its proprietary antibody technology platform, today announced the appointment of Dr. David Stover, Ph.D., to the company’s board of directors.
An accomplished pharmaceutical researcher and scientist, Dr. Stover has more than 25 years of experience in both small-molecule and biologics drug discovery and development. Most recently, he served as head of Agensys, Inc., an Astellas Pharma affiliate focused on antibody and antibody drug conjugate development, where he led a team of 240 employees in the research, clinical manufacturing and development of five investigational new drugs and four clinical proof of concepts during a 5-year period.
“Dr. Stover brings to Meditope considerable experience in the engineering and development of novel antibody-based therapeutics,” said Stephanie Hsieh, president and chief executive officer at Meditope. “David’s appointment represents an expansion to our board helping advance our exciting new Meditope-enabled immune-oncology candidates while leveraging our technology’s relevance across a broad spectrum of applications.”
Dr. Stover also founded the Oncology Biologics department at Novartis, where he served as its director, developing three clinical product candidates. Previously, he held the position of vice president of drug discovery at MDS Proteomics, where he managed research sites in Cambridge., Mass., Charlottesville, Va., and Toronto. Earlier in his career, Dr. Stover was the first employee and director of biochemistry at Kinetix Pharmaceuticals, a small-molecule kinase inhibitor company that was acquired by Amgen in 2000.
Dr. Stover earned his Ph.D. in biochemistry at the University of Washington and holds a Bachelor of Science degree in zoology from Duke University.
About Meditope Biosciences, Inc.
Meditope Biosciences is a biotechnology company developing novel antibody-based cancer products using its SnAP technology (Site-specific novel Antibody Platform). Discovered at City of Hope, a National Cancer Institute designated Comprehensive Cancer Center, SnAP is capable of turning any antibody into a proprietary, site-specific “LEGO-like” system that is able to attach and detach nearly anything to an antibody without the need for chemical conjugation. Meditope’s SnAP technology has the potential to advance the antibody market by producing an array of new therapeutic and diagnostic products. More information can be found by visiting www.meditope.com.